A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System
Head and Neck Cancer, Thoracic Cancer, Abdominal Cancer
About this trial
This is an interventional other trial for Head and Neck Cancer
Eligibility Criteria
Inclusion Criteria: Patient is scheduled to receive radiation therapy to one of the following anatomical sites: head and neck/brain, thorax, abdomen, pelvis. Patient is at least 18 years of age. If the patient will be receiving IV contrast on study, patient must have adequate renal function as defined by an estimated glomerular filtration rate (eGFR) of >30. Note: if no IV contrast will be administered on study, patient may enroll without creatinine level documented. Contrast eligibility will be determined as per Appendix A. If the patient is a woman of childbearing potential, patient must have a negative pregnancy test within 30 days of enrollment and prior to any study imaging. Contraceptive use is not an adequate documentation of no chance of pregnancy. Exclusion Criteria: Patient is unwilling or unable to sign an IRB-approved written informed consent document. Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response").
Sites / Locations
- University Hospitals Cleveland Medical CenterRecruiting
Arms of the Study
Arm 1
Experimental
HyperSight Imaging arm
Subjects are imaged with the new HyperSight CBCT imaging system.